In addition, the differences in cell type (B-cell lymphoma versus colon carcinoma) and source of analog-sensitive CDK9 (endogenously expressed versus excess of recombinantly purified) may provide further explanation. This evidence concerns the gene CDK9 and B-cell non-Hodgkin lymphoma.